News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Transkaryotic Therapies, Inc. (TKTX) Announces Appointment Of Eric Pauwels As Senior Vice President, Global Commercial Operations

10/19/2005 5:13:09 PM

CAMBRIDGE, Mass., March 29 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. today announced that Eric Pauwels will join the company as Senior Vice President, Global Commercial Operations effective April 13, 2005. In this position, Mr. Pauwels will have overall responsibility for TKT's worldwide commercialization initiatives, including the potential launch of iduronate-2-sulfatase (I2S) for Hunter syndrome and ongoing marketing efforts for Replagal(TM), TKT's enzyme replacement therapy for Fabry disease. In addition, Mr. Pauwels will provide commercial input on the prioritization and value of TKT's emerging new product pipeline.

"Eric joins TKT at an exciting time as we prepare to expand our marketing and sales efforts and introduce new products to the marketplace," said David D. Pendergast, Ph.D., Executive Vice President and Chief Operating Officer of TKT. "With nearly twenty years of commercial pharmaceutical experience, Eric has successfully led marketing and sales activities in the United States, Europe and Asia. Eric will play a significant role in expanding TKT's commercial expertise and will provide strong direction to TKT as we execute on new initiatives, including our anticipated first commercial U.S. launch in 2006."

Mr. Pauwels joins TKT from Bayer Healthcare Pharmaceuticals where he most recently managed the global commercialization for LEVITRA(R) for erectile dysfunction in his role as Vice President Global Strategic Marketing, Men's Health. Previously, he was Vice President Global Strategic Marketing, Cardiovascular at Bayer and held several positions of increasing responsibility in sales and marketing at Laboratories Fournier for more than four years. Mr. Pauwels has also held marketing and sales positions at Janssen Pharmaceutica Products and McNeil Pharmaceuticals where he managed several product launches, including RISPERDAL(R) for psychotic disorders. He received a B.Sc. from California State Polytechnic University, Pomona.

About TKT

Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. In addition to its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and South America. Additional information about TKT is available on the company's website at

This press release contains forward-looking statements regarding TKT's management structure, as well as statements containing the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including whether TKT will successfully manage its marketing and sales operations; the impact of competing products on Replagal; whether the FDA and equivalent regulatory authorities will approve I2S on a timely basis, or at all; and other factors set forth under the caption "Certain Factors That May Affect Future Results" in the company's Annual Report on Form 10-K for the year ended December 31, 2004, which is on file with the Securities and Exchange Commission and are incorporated herein by reference. While the company may elect to update forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its expectations change.

Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA. LEVITRA(R) is a registered trademark of Bayer Healthcare Pharmaceuticals and RISPERDAL(R) is a registered trademark of Janssen Pharmaceutica Products, L.P.

For More Information Contact: Justine E. Koenigsberg Senior Director, Corporate Communications (617) 349-0271 Daniella M. Lutz Manager, Corporate Communications (617) 349-0205

Photo: NewsCom: Archive: Photo Desk, photodesk@prnewswire.comTranskaryotic Therapies, Inc.

CONTACT: Justine E. Koenigsberg, Senior Director, CorporateCommunications, +1-617-349-0271, or Daniella M. Lutz, Manager, CorporateCommunications, +1-617-349-0205, both of Transkaryotic Therapies, Inc.

Read at

comments powered by Disqus